Strongbridge Biopharma plc Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference
COR-003, Strongbridge’s lead product candidate, is a cortisol inhibitor currently being studied in the global Phase 3 SONICS trial for the treatment of endogenous Cushing's syndrome.
“Strongbridge is proud to be a part of the rare disease community and scientific exchange taking place at the Endocrine Society’s 2016 Annual Meeting,” said
The poster, entitled Pharmacology of COR-003 (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome, was presented on
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements. These statements relate to future events and involve known and unknown risks, including, without limitation, uncertainties regarding Strongbridge's strategy, plans, outcomes of product development efforts and objectives of management for future operations. The words "anticipate," "estimate," "expect," "intend," "may," "plan," "potential," "project," "target," "will," "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.
Contacts: Corporate and Media Relations Elixir Health Public Relations
Lindsay M. Rocco+1 862-596-1304 [email protected] Investor Relations ICR Inc. Stephanie Carrington+1 646-277-1282 [email protected] USA 900 Northbrook DriveSuite 200 Trevose, PA19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389